top of page

News

Dr. Smith spoke at the Fletcher Allen Health Care Center at the University of Vermont.


Subsequently, Dr. Smith presented data obtained from the baseline visit of patients enrolled in the Nuedexta Bulbar Function treatment trial at the annual meeting of the American Academy of Neurology. As of May 2nd, 43 persons out of a planned enrollment of 60 were enrolled in the nationwide treatment trial that is being conducted at seven ALS centers.


Dr. Smith served as a panel member for a session at the 2014 California ALS Research Summit that focused on the treatment of ALS with antisense therapeutics. Furthermore, he presented a brief overview of a hypothesis regarding the spread of ALS within the nervous system. For more information about the ALS Summit, click here.

As a finale for 2013, CNS was privileged to be included in a manuscript that was published in the Proceedings of the National Academy of Science. This work, spearheaded by Dr. Brian Kaspar, demonstrated in-vitro that supportive cells in the brain (astrocytes) are toxic to motor neurons, thus creating an ideal test tube model of ALS. This study should greatly facilitate research into the cause and treatment of ALS.

© 2021 by Center for Neurologic Study.

bottom of page